Springer Health+ IME: Podcast to Practice
Oct 9, 2026 · 18 min · 9 segments
Decoding HER2 mutations and overexpression in NSCLC In episode 3 Enriqueta Felip and Egbert Smit look at the future directions in HER2-positive NSCLC; ongoing clinical trials, emerging novel agents…
Enriqueta FelipHost
Thank you, Egbert, because you also, uh, mentioned and discussed, uh, the most important challenges that we, uh, have in this, uh, scenario, you know.
Uh, even, uh, in some places, testing is, uh, still an issue, you know, because we need, uh, testing in, in a tumor and sometimes in liquid biopsy and also access, you know.
So, uh, if I had, uh, to summarize the most important, uh, points we discussed today, uh, I- I- I think I- I- I would, uh, emphasize that HER2 mutation is clearly an actionable genomic alterations.
Uh, the therapies that we discussed, uh, are moving into a first-line treatment, and, uh, we have, uh, highly innovative, uh, HER2-targeted agents also, uh, in development.
And perhaps, Egbert, if you could please summarize the most important takeaway, uh, takeaways, uh, from this episode.
And once we have these drugs available, I think we should treat those pa- those patients with HER2 mutations and maybe with HER2 overexpression with the right targeted agent.
Thank you, Egbert, because you also, uh, mentioned and discussed, uh, the most important challenges that we, uh, have in this, uh, scenario, you know.
Uh, even, uh, in some places, testing is, uh, still an issue, you know, because we need, uh, testing in, in a tumor and sometimes in liquid biopsy and also access, you know.
So, uh, if I had, uh, to summarize the most important, uh, points we discussed today, uh, I- I- I think I- I- I would, uh, emphasize that HER2 mutation is clearly an actionable genomic alterations.
Uh, the therapies that we discussed, uh, are moving into a first-line treatment, and, uh, we have, uh, highly innovative, uh, HER2-targeted agents also, uh, in development.
And perhaps, Egbert, if you could please summarize the most important takeaway, uh, takeaways, uh, from this episode.
And once we have these drugs available, I think we should treat those pa- those patients with HER2 mutations and maybe with HER2 overexpression with the right targeted agent.
The rest of this transcript — segmented and speaker-labeled, so you land on the exact moment something was said
Search every transcript — by keyword, by phrase, or by meaning, across every show Radar indexes
Trends — what is surging across podcasts, measured against its own baseline
Alerts — when a name you follow appears in a newly indexed episode
No account is needed to search Radar.
